文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

多中心自膨胀式经导管肺动脉瓣置换术注册研究早期结果

Early Outcomes From a Multicenter Transcatheter Self-Expanding Pulmonary Valve Replacement Registry.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

该多中心注册研究纳入243例原生右室流出道肺动脉反流患者,评估自膨胀式Harmony瓣膜行经导管肺动脉瓣置换术的安全性与短期有效性。中位随访13个月,98%患者血流动力学功能可接受,1年免除复合临床结局达99%,短期结果优异。

要点

  • 自膨胀式TPVR在多中心真实世界中技术成功率高,严重不良事件少。
  • 中位随访13个月,98%患者血流动力学功能可接受,1年免除复合结局99%。
  • 术后室性心律失常需治疗者占19%,需关注围术期心律失常管理。

核心结论

  • 在这项大规模多中心真实世界经验中,自膨胀式TPVR的短期临床和血流动力学结果优异。

研究设计与样本

  • 多中心注册研究,连续纳入截至2022年4月30日在美国11个中心接受TPVR的原生RVOT肺动脉反流患者,共243例。

主要发现

  • 患者中位年龄31岁(Q1-Q3:19-45岁),心脏诊断法洛四联症71%、瓣膜性肺动脉狭窄21%、其他8%。
  • 除1例外均获急性技术成功,手术严重不良事件发生率4%,无器械栓塞或死亡。
  • 86%患者住院时间为1天,需治疗的室性心律失常发生率为19%。
  • 中位随访13个月(Q1-Q3:8-19个月)时98%患者血流动力学功能可接受。
  • 估计1年免除复合临床结局99%、2年96%;1年免除TPVR相关心内膜炎98%;5例死亡(COVID-19 1例、不明原因2例、血流感染2例)。

关键数值与推荐

  • 主要结局为血流动力学功能障碍(肺动脉反流大于轻度且RVOT平均压差>30 mmHg)与RVOT再干预的复合终点。

临床怎么用

  • 对于原生或外科修复后RVOT肺动脉反流患者,自膨胀式TPVR可作为短期安全有效的治疗选择。
  • 术后需关注室性心律失常及感染性心内膜炎风险,并进行规律随访。

局限性

  • 随访时间较短(中位13个月),长期结局尚需继续随访该队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcatheter pulmonary valve replacement (TPVR) with the self-expanding Harmony valve (Medtronic) is an emerging treatment for patients with native or surgically repaired right ventricular outflow tract (RVOT) pulmonary regurgitation (PR). Limited data are available since U.S. Food and Drug Administration approval in 2021. OBJECTIVES: In this study, the authors sought to evaluate the safety and short-term effectiveness of self-expanding TPVR in a real-world experience. METHODS: This was a multicenter registry study of consecutive patients with native RVOT PR who underwent TPVR through April 30, 2022, at 11 U.S. CENTERS: The primary outcome was a composite of hemodynamic dysfunction (PR greater than mild and RVOT mean gradient >30 mm Hg) and RVOT reintervention. RESULTS: A total of 243 patients underwent TPVR at a median age of 31 years (Q1-Q3: 19-45 years). Cardiac diagnoses were tetralogy of Fallot (71%), valvular pulmonary stenosis (21%), and other (8%). Acute technical success was achieved in all but 1 case. Procedural serious adverse events occurred in 4% of cases, with no device embolization or death. Hospital length of stay was 1 day in 86% of patients. Ventricular arrhythmia prompting treatment occurred in 19% of cases. At a median follow-up of 13 months (Q1-Q3: 8-19 months), 98% of patients had acceptable hemodynamic function. Estimated freedom from the composite clinical outcome was 99% at 1 year and 96% at 2 years. Freedom from TPVR-related endocarditis was 98% at 1 year. Five patients died from COVID-19 (n = 1), unknown causes (n = 2), and bloodstream infection (n = 2). CONCLUSIONS: In this large multicenter real-world experience, short-term clinical and hemodynamic outcomes of self-expanding TPVR therapy were excellent. Ongoing follow-up of this cohort will provide important insights into long-term outcomes.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Goldstein BH, McElhinney DB, Gillespie MJ, et al. Early Outcomes From a Multicenter Transcatheter Self-Expanding Pulmonary Valve Replacement Registry. J Am Coll Cardiol. 2024. PMID: 38569760. doi:10.1016/j.jacc.2024.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。